CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB.
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML.
Ikoma Y, Nakamura N, Kaneda Y, Takamori H, Seki T, Hiramoto N, Kitagawa J, Kanda J, Fujita K, Morishita T, Ochi Y, Chiba S, Sasaki N, Ichii M, Imada K, Watanabe M, Hishizawa M, Miyahara Y, Maesako Y, Tanaka Y, Oka S, Tsuji M, Yoshihara S, Mitani K, Ueda Y, Kitano T, Watanabe M, Sezaki N, Kondo T, Kasahara S, Takaori-Kondo A, Kanemura N, Ogawa S, Nannya Y.